Matziolis G, Perka C, Disch A, Zippel H
Department of Orthopaedics, Charité University Hospital, Schumannstr. 20-21, 10117 Berlin, Germany.
Calcif Tissue Int. 2003 Oct;73(4):370-9. doi: 10.1007/s00223-002-2091-5. Epub 2003 Jul 24.
The objective of the this study was to examine the effects of fondaparinux, a synthetic anticoagulant substance similar to heparin, on osteoblasts compared with previously used heparins. Its effects have been shown in clinical trials to be highly effective in thromboembolism prophylaxis. Unfractionated heparin (UFH), dalteparin, enoxaparin and fondaparinux were added to osteoblast cultures in the therapeutic range and two decimal powers above and below it in each case. The results showed that the mitochondrial activity and protein synthesis of osteoblasts treated with fondaparinux were significantly higher than in the other groups. Similar effects could be demonstrated for the matrix collagen type II content and calcification. In contrast enoxaparin, dalteparin and UFH lead to a significant decrease of matrix collagen type II content and calcification in concentrations equal or higher than the therapeutic one. No inhibitory in-vitro effects of fondaparinux on human osteoblasts could be demonstrated within the concentration range investigated (0.01-100 microg/ml). We conclude that fondaparinux can be used to avoid the heparin-related negative influence on osteoblast-dependent fracture healing and endoprosthetic implant integration.
本研究的目的是与先前使用的肝素相比，研究磺达肝癸钠（一种类似于肝素的合成抗凝血物质）对成骨细胞的影响。其效果在临床试验中已显示对预防血栓栓塞非常有效。将普通肝素（UFH）、达肝素、依诺肝素和磺达肝癸钠在治疗范围内以及在每种情况下高于和低于该范围两个数量级的浓度添加到成骨细胞培养物中。结果表明，用磺达肝癸钠处理的成骨细胞的线粒体活性和蛋白质合成明显高于其他组。对于II型基质胶原蛋白含量和钙化也可显示出类似效果。相比之下，依诺肝素、达肝素和UFH在等于或高于治疗浓度时会导致II型基质胶原蛋白含量和钙化显著降低。在所研究的浓度范围（0.01 - 100微克/毫升）内，未证明磺达肝癸钠对人成骨细胞有体外抑制作用。我们得出结论，磺达肝癸钠可用于避免肝素对成骨细胞依赖性骨折愈合和假体植入整合的相关负面影响。
